Evidence map›Paper›PMID 35909244›Full record

ArticleCancer science2022

Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).

Dai Maruyama, Shinsuke Iida, Ryunosuke Machida, Shigeru Kusumoto, Noriko Fukuhara, Nobuhiko Yamauchi, Kana Miyazaki, Makoto Yoshimitsu, Junya Kuroda, Norifumi Tsukamoto and 18 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Dai MaruyamaDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID 0000-0003-0654-6920
Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.ORCID 0000-0002-4951-960X
Ryunosuke MachidaJCOG Data Center, National Cancer Center Hospital, Tokyo, Japan.
Shigeru KusumotoDepartment of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.
Noriko FukuharaDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.
Nobuhiko YamauchiDepartment of Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
Kana MiyazakiDepartment of Hematology and Oncology, Mie University School of Medicine, Tsu, Japan.
Makoto YoshimitsuDepartment of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.ORCID 0000-0002-5935-0385
Junya KurodaDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID 0000-0001-6130-1550
Norifumi TsukamotoDepartment of Hematology, Gunma University Hospital, Maebashi, Japan.
Hideki TsujimuraDivision of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.ORCID 0000-0002-1216-4470
Takahiro YamauchiDepartment of Hematology and Oncology, University of Fukui, Fukui, Japan.ORCID 0000-0002-6531-812X
Takahiko UtsumiDepartment of Hematology, Shiga General Hospital, Moriyama, Japan.
Ishikazu MizunoDepartment of Hematology, Hyogo Cancer Center, Akashi, Japan.
Yasushi TakamatsuDivision of Medical Oncology, Hematology and Infectious Diseases, Fukuoka University Hospital, Fukuoka, Japan.
Yasuyuki NagataDepartment of Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Eiichi OhtsukaDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Ichiro HanamuraDivision of Hematology, Aichi Medical University, Nagakute, Japan.ORCID 0000-0002-6681-8927
Yasuhiro SuzukiDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Shinichiro YoshidaDepartment of Hematology, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan.
Satoshi YamasakiDepartment of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Youko SuehiroDepartment of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Yutaro KamiyamaDepartment of Clinical Oncology and Hematology, The Jikei University Hospital, Tokyo, Japan.
Suguru FukuharaDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0002-2423-9978
Kunihiro TsukasakiDepartment of Hematology, International Medical Centre, Saitama Medical University, Saitama, Japan.
Hirokazu NagaiDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Funding

Grant-in-Aid for Clinical Cancer Research from the Ministry of Health, Labour and Welfare of Japan H26-kakushin-teki-gan-ippan-074Japan Agency for Medical Research and Development 21ck0106685h0001Japan Agency for Medical Research and Development JP16ck0106077Japan Agency for Medical Research and Development JP19ck0106348National Cancer Center Research and Development Funds 2020-J-3National Cancer Center Research and Development Funds 26-A-4National Cancer Center Research and Development Funds 29-A-3
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaBortezomibClinical Trials, Phase II as TopicHumansMelphalanPrednisoloneRandomized Controlled Trials as TopicBortezomibMelphalanPrednisolone

Identifiers

PMID35909244
PMCPMC9459263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.